BRIEF-Xvivo Perfusion Q1 EBITDA up at SEK 7.3 million

* Q1 operating income before depreciation and amortization (EBITDA) excluding one-time

expenses amounted to 7.3 million Swedish crowns ($897,357), corresponding to EBITDA margin of 22

percent, versus an EBITDA of 4.5 million crowns a year ago

Read more